Theravance Biopharma (NASDAQ:TBPH) Earns “Hold (C)” Rating from Weiss Ratings

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “hold (c)” rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages also recently commented on TBPH. Jones Trading raised shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, June 17th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. BTIG Research upped their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, June 27th. B. Riley began coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.00.

Theravance Biopharma Stock Up 0.6%

Shares of NASDAQ TBPH opened at $14.44 on Wednesday. Theravance Biopharma has a 52 week low of $7.88 and a 52 week high of $15.15. The firm’s fifty day moving average is $13.44 and its 200 day moving average is $11.20. The company has a market cap of $727.20 million, a price-to-earnings ratio of 60.17 and a beta of -0.03.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president directly owned 326,918 shares of the company’s stock, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors have recently bought and sold shares of TBPH. GAMMA Investing LLC grew its position in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 3,281 shares during the last quarter. Rhumbline Advisers grew its position in Theravance Biopharma by 3.8% during the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock valued at $556,000 after purchasing an additional 2,293 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Theravance Biopharma by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock valued at $1,049,000 after acquiring an additional 1,720 shares during the period. Tabor Asset Management LP bought a new position in Theravance Biopharma during the 1st quarter valued at about $135,000. Finally, Brookwood Investment Group LLC bought a new position in Theravance Biopharma during the 1st quarter valued at about $188,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.